Cipla, a third largest pharma major in India with sales of Rs.6800 crore, has posted satisfactory performance during the year ended March 2012. Its standalone net profit increased by 17.1 per cent to Rs.1,124 crore from Rs.960 crore in the previous year. Its EBDITA also grew by 22.5 per cent to Rs.1,730 crore from Rs.1,412 crore. With better growth in profits, its earnings per share increased to Rs.14 from Rs.11.96 in the last year.

The company's standalone net sales increased by 11.3 per cent to Rs.6,808 crore from Rs.6,116 crore in the previous year. Its domestic sales improved by 13.8 per cent to Rs.3,213 crore from Rs.2,822 crore and its exports grew by 9.8 per cent to Rs.3,692 crore from Rs.3,361 crore. Its exports of formulations improved by 10.6 per cent to Rs.2,968 crore from Rs.2,682 crore and that of APIs went up by 6.6 per cent to Rs.724 crore.

Cipla's material cost has decreased by more than 7 per cent due to changes in product mix, viz lower proportion of anti-retrovirals and higher contribution of anti-asthma as well as anti-malarial segment coupled with increased realizations. As a results, operating margins have also increased by about 4 per cent.